Adial Pharmaceuticals, Inc. (ADIL)
Adial Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Glen Allen, VA, US. The stock last traded at $4.32, up 0.23% on the session, giving a market capitalisation of $4.1M. On trailing twelve-month figures it carries a trailing P/E of -0.44, a net margin of 0.0%. Its beta of 1.43 implies it has historically moved more than the broad market.
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Adial Pharmaceuticals, Inc. is most often compared with the following Healthcare names: